Northwestern University

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024

Retrieved on: 
金曜日, 5月 10, 2024
Inflammation, RNA, UC, Hepatology, Patient, Northwestern University, CBC, Associate, Division

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

Key Points: 
  • Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2
    Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
    Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Abivax has also sponsored a Product Theater presentation titled, “ An Investigational New MOA that Can Stabilize the Inflammatory Response in Ulcerative Colitis ,” taking place on May 20, 2024, at 2:30-3:15 p.m. EDT in room “DDW Theater 1,” featuring Prof. Parambir S. Dulai, M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois, U.S.

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

Retrieved on: 
木曜日, 5月 9, 2024
Plus Therapeutics, Northwestern University, LM, PSTV, Hematology, Breast, Lung cancer, CNS, Incidence, Patient, Acquisition, MRI, Neuro, Central nervous system, Clinical trial, Plus, Associate, Therapy, Cancer, Medical imaging

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.

Key Points: 
  • Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™” and discussed potential partnering opportunities
    AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.
  • “Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern University & The Feinberg School of Medicine.
  • Plus discussed its plan to develop the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate rhenium (Re186) obisbemeda, and to seek partnering opportunities for CNSide.
  • Plus presented topline clinical trial data from the FORESEE trial which met its primary endpoint of clinical utility for the CNSide test in 40 patients with LM due to either breast or non-small cell lung cancer; a presentation of the full analysis is planned for the August 8-10 SNO/ASCO Meeting in Denver, CO.
    “Better diagnostics for leptomeningeal metastases are a clinical imperative for these patients and will help increase the market for our lead radiotherapeutic candidate rhenium (Re186) obisbemeda,” said Dr. Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024

Retrieved on: 
水曜日, 5月 8, 2024
Inflammation, RNA, UC, Hepatology, Patient, Northwestern University, CBC, Associate, Division

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

Key Points: 
  • Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2
    Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
    Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Abivax has also sponsored a Product Theater presentation titled, “ An Investigational New MOA that Can Stabilize the Inflammatory Response in Ulcerative Colitis ,” taking place on May 20, 2024, at 2:30-3:15 p.m. EDT in room “DDW Theater 1,” featuring Prof. Parambir S. Dulai, M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois, U.S.

Dion Cornett Joins Tatum as Chief Executive Officer

Retrieved on: 
火曜日, 5月 7, 2024
Northwestern University, Octopus Group, United States Naval Academy, Red Hat, MBA, Software, MariaDB, Web3, Kellogg School, Growth, DBeaver

LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.
  • Dion brings to Tatum two decades of experience in the software industry and an exceptional track record in successfully scaling businesses through product led growth.
  • Dion Cornett is recognized as an expert in open-source software and database technologies, having held senior leadership positions at Red Hat, MariaDB, ReachForce, Liquibase and DBeaver.
  • "I am excited to join Tatum and work with a talented team that is passionate about leveraging blockchain technology to redefine our digital future," said Dion Cornett.

Dion Cornett Joins Tatum as Chief Executive Officer

Retrieved on: 
火曜日, 5月 7, 2024
Northwestern University, Octopus Group, United States Naval Academy, Red Hat, MBA, Software, MariaDB, Web3, Kellogg School, Growth, DBeaver

LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- Tatum, a leading platform for blockchain application development, is thrilled to announce the appointment of Dion Cornett as its new Chief Executive Officer.
  • Dion brings to Tatum two decades of experience in the software industry and an exceptional track record in successfully scaling businesses through product led growth.
  • Dion Cornett is recognized as an expert in open-source software and database technologies, having held senior leadership positions at Red Hat, MariaDB, ReachForce, Liquibase and DBeaver.
  • "I am excited to join Tatum and work with a talented team that is passionate about leveraging blockchain technology to redefine our digital future," said Dion Cornett.

SFA Therapeutics Strengthens Management Team with Appointment of Chief Medical Officer

Retrieved on: 
木曜日, 5月 2, 2024
Stanford University, Skin, SVKM's NMIMS, OM1, Inflammation, MD, SFA, Artificial intelligence, Yale University, Fellow, Therapy, Master of Science, Kellogg School, Psoriasis, Northwestern University, Health, MBA, Cohort (statistics), Medical device

JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the appointment of Stefan C. Weiss, MD, MBA, as Chief Medical Officer.

Key Points: 
  • JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the appointment of Stefan C. Weiss, MD, MBA, as Chief Medical Officer.
  • "Dr. Weiss brings decades of multi-faceted clinical and industry experience in both dermatology and immunology," commented Ira Spector, Ph.D., CEO of SFA Therapeutics.
  • "I am honored to join the SFA Therapeutics team to help shape the clinical pathway forward for SFA-002 and other candidates that target inflammatory disease.
  • As a practicing dermatologist, I have witnessed the immense need for novel therapeutics with greater efficacy and fewer side effects than the currently available treatments for chronic inflammatory skin conditions," stated Dr. Weiss, Chief Medical Officer of SFA Therapeutics.

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Retrieved on: 
水曜日, 4月 17, 2024
MASH, Executive, Marketing, Eli Lilly, Genentech, Biotechnology Innovation Organization, Piz Sardona, Liver, Patient, Acquisition, Circulatory system, Northwestern University, Eli Lilly and Company, Trade, Therapy, SAN, Pharmaceutical industry

Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.

Key Points: 
  • Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.
  • “As 89bio executes on its ongoing Phase 3 programs for pegozafermin, this is an opportune time to add an industry leader like Martin to our board,” said Rohan Palekar, Chief Executive Officer of 89bio.
  • Mr. Babler previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development.
  • I am excited to work alongside the management team and Board of Directors to bring pegozafermin to the many patients in need.”

Resilient Waters Fund Wins the 2024 Kellogg-Morgan Stanley Sustainable Investing Challenge

Retrieved on: 
月曜日, 4月 22, 2024
Sustainability, Environment, Finance, Environmental, Social and Governance (ESG), Banking, Professional Services, University, Education, Great Salt Lake, Seed, Risk, Morgan Stanley, Kellogg School of Management, Socially responsible investing, Human back, Water, Business, Farmer, Northwestern University, Columbia Business School, Creativity, Student, Renewable energy

The Morgan Stanley Institute for Sustainable Investing and Kellogg School of Management at Northwestern University today announced that the Resilient Waters Fund team was named the winner of the 14th annual Kellogg-Morgan Stanley Sustainable Investing Challenge.

Key Points: 
  • The Morgan Stanley Institute for Sustainable Investing and Kellogg School of Management at Northwestern University today announced that the Resilient Waters Fund team was named the winner of the 14th annual Kellogg-Morgan Stanley Sustainable Investing Challenge.
  • The winning team was one of 12 finalists selected from a competitive field, which included 84 teams comprised of 290 students from 44 countries.
  • The Resilient Waters Fund would catalyze federal, state and investment funds through a creative land trust mechanism to spur irrigation efficiency, responsible cropping and water savings.
  • “Through the Sustainable Investing Challenge, students develop financial solutions to real-world issues, providing them with invaluable experience and insights into sustainable finance,” says Jessica Alsford, Morgan Stanley’s Chief Sustainability Officer and CEO of the Institute for Sustainable Investing.

FREYR Battery Announces the Appointments of Todd Kantor, Tore Ivar Slettemoen, and David Manners to the Board of Directors

Retrieved on: 
金曜日, 4月 19, 2024
Batteries, Other Manufacturing, Alternative Energy, EV, Electric Vehicles, Energy, Automotive, Technology, Manufacturing, Citadel, Georgetown University, University, SVKM's NMIMS, Mechanical engineering, Acceleration, Battery, Mechanical, Entrepreneurship, Master of Science, Kellogg School, Goizueta Business School, Northwestern University, MBA, Emory University, Government, Growth

FREYR Battery (NYSE: FREY) (“FREYR” or the “Company”), a developer of clean, next-generation battery cell production capacity, has appointed Todd Kantor, Tore Ivar Slettemoen, and David Manners to the Company’s Board of Directors (“Board”) effective immediately.

Key Points: 
  • FREYR Battery (NYSE: FREY) (“FREYR” or the “Company”), a developer of clean, next-generation battery cell production capacity, has appointed Todd Kantor, Tore Ivar Slettemoen, and David Manners to the Company’s Board of Directors (“Board”) effective immediately.
  • “I am delighted to welcome Todd, Tore Ivar, and David to FREYR’s Board of Directors,” commented Tom Einar Jensen, Co-Founder and Executive Chairperson of FREYR.
  • He has nearly 25 years of experience in the global energy markets as a portfolio manager, analyst, trader, and investment banker.
  • “As an emerging battery producer, FREYR has a vital role to play in the development of the nascent Western hemisphere battery industry.

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Retrieved on: 
水曜日, 4月 10, 2024
Oncology, Health, Genetics, Other Health, Other Science, Science, Biotechnology, Steps, Education, Risk, Esophageal cancer, ECAN, CPI, Research, Hepatology, GI, Disease, Patient, Physician, Northwestern University, Diagnosis, GERD, Castle, FACP, Division, Gastroesophageal reflux disease, FACG, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.
  • The Company is proud to continue its ongoing collaboration with the Esophageal Cancer Action Network (ECAN), Gastro Broadcast podcast and EndoscopyNow to help advance esophageal cancer research, prevention, education and advocacy.
  • “Unfortunately, esophageal cancer is often detected at its late stages and the five-year survival rate of esophageal cancer patients is less than 20%,”1 said Emmanuel Gorospe, M.D., MPH, CPI, FACP, FACG, FASGE, GI Medical Director at Castle Biosciences.
  • TissueCypher® is Castle’s prognostic risk-stratification test designed to predict progression to high-grade dysplasia or esophageal cancer.